Vitiligo Treatment Advancement

Exciting progress continues to emerge in the ongoing effort to advance nonsegmental vitiligo research, particularly in evaluating how combining narrow-band UVB (NB-UVB) phototherapy with topical Janus kinase (JAK) inhibitors can safely accelerate repigmentation and prevent premature treatment discontinuation. As the dermatology landscape shifts toward more nuanced, multi-modality treatment regimens, demonstrating the real-world operational viability of these complex protocols is paramount for upcoming clinical pipelines.

Among the key contributors and investigators to this clinical milestone is Dr. Ira Thorla at LA Dermatology Associates in Baton Rouge, LA, a premier site within the DelRicht Research network. Serving as both a contributing author and principal investigator, Dr. Thorla played a key role in supporting the clinical execution of this Phase 2 program targeting patients aged  ≥12 years and diagnosed with nonsegmental vitiligo. With 18 years of specialized experience, Dr. Thorla’s participation underscores how essential seasoned principal investigators and site networks are to executing intricate protocols, ensuring high enrollment compliance, clean source data capture, and impactful contributions to clinical advancement in dermatological studies.

The publication details that “this exploratory phase 2 study evaluated whether adding NB-UVB treatment to ruxolitinib cream accelerated repigmentation among patients who did not achieve T-VASI25 within the first 3 months of ruxolitinib cream monotherapy.” The 12-week timeline is operationally vital, as data suggests “patients may become disappointed or impatient and stop treatment prematurely in the absence of sufficient improvement within 3 months.” By intervening with combination therapy, the trial achieved impressive clinical benchmarks. The text notes that “patients who had <T-VASI25 at week 12 with ruxolitinib cream monotherapy and received combination NB-UVB therapy for up to 36 weeks showed evidence of accelerated improvement in repigmentation.” Specifically, the data showed that “mean percentage change from baseline in T-VASI improved from −7.9% at week 12 to −50.4% at week 48,” with “58% achieving T-VASI50 at week 48.” Furthermore, the co-administration yielded excellent results on the face, where “F-VASI mean percentage change improved to −40.6% at week 16 and further improved to −85.6% at week 48.”

Efforts led by the Incyte team demonstrate how operational innovation remains central to the future of dermatology drug development, showcasing that concomitant at-home phototherapy does not impact topical pharmacokinetics or blood plasma concentrations while dramatically boosting success rates. Rachel Hastings, Managing Partner at DelRicht Research, commented:

“Dermatology studies like this are critical to ensuring we deliver both speed and predictability to our trial sponsors while helping vitiligo patients gain access to repigmentation pathways that reflect the current landscape of medicine. By evaluating complex, multi-modality combination frameworks in real-world clinic settings, our site network is proving that we can maintain strict protocol fidelity and high patient compliance to deliver clean, submission-ready data.”

 

– Rachel Hastings, DelRicht Research Managing Partner

Accelerating Research and Publication Contribution

The newly posted publication, “Efficacy and Safety of Ruxolitinib Cream Combined With Narrow-Band UVB Phototherapy for Treatment of Vitiligo,” was featured in the Journal of Investigative Dermatology (JID). As a top-tier forum for cutaneous biology, JID provides a premier platform for data that actively shapes future sponsor trial designs and clinical practice paradigms globally.

DelRicht Research is proud to be part of this broader scientific community, one that is committed to moving medicine forward through structural innovation, operational excellence, and patient-centered clinical trial execution. Contributions from dedicated network investigators like Dr. Thorla ensures that complex study designs translate smoothly into rapid database locks and real-world therapeutic impact. For sponsors and CROs looking to pioneer the next generation of dermatological therapies, this trial serves as a blueprint for successful site-sponsor collaboration.

For further information, read the full publication: here